JP2008509914A - ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法 - Google Patents

５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法 Download PDF

Info

Publication number
JP2008509914A
JP2008509914A JP2007525753A JP2007525753A JP2008509914A JP 2008509914 A JP2008509914 A JP 2008509914A JP 2007525753 A JP2007525753 A JP 2007525753A JP 2007525753 A JP2007525753 A JP 2007525753A JP 2008509914 A JP2008509914 A JP 2008509914A
Authority
JP
Japan
Prior art keywords
acid
dpb
salt
diphenylbarbituric
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2007525753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509914A5 (enExample
Inventor
ダニエラ ガットマン
アヴラハム ヤコビー
ダニエル モローズ
バリー レヴィット
ハワード ラットマン
Original Assignee
タロー・ファーマシューティカル・インダストリーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タロー・ファーマシューティカル・インダストリーズ・リミテッド filed Critical タロー・ファーマシューティカル・インダストリーズ・リミテッド
Publication of JP2008509914A publication Critical patent/JP2008509914A/ja
Publication of JP2008509914A5 publication Critical patent/JP2008509914A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C07D239/64—Salts of organic bases; Organic double compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007525753A 2004-08-10 2005-08-10 ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法 Ceased JP2008509914A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60032704P 2004-08-10 2004-08-10
PCT/US2005/028380 WO2006026095A2 (en) 2004-08-10 2005-08-10 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013118224A Division JP2013177442A (ja) 2004-08-10 2013-06-04 ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2008509914A true JP2008509914A (ja) 2008-04-03
JP2008509914A5 JP2008509914A5 (enExample) 2008-09-25

Family

ID=34942111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007525753A Ceased JP2008509914A (ja) 2004-08-10 2005-08-10 ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
JP2013118224A Pending JP2013177442A (ja) 2004-08-10 2013-06-04 ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013118224A Pending JP2013177442A (ja) 2004-08-10 2013-06-04 ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法

Country Status (14)

Country Link
EP (2) EP1625848A1 (enExample)
JP (2) JP2008509914A (enExample)
KR (2) KR20070074549A (enExample)
CN (2) CN102512422A (enExample)
AT (1) ATE510541T1 (enExample)
AU (1) AU2005280419B2 (enExample)
BR (1) BRPI0513337A (enExample)
CA (1) CA2576832C (enExample)
IL (1) IL181247A (enExample)
MX (1) MX2007001655A (enExample)
NZ (1) NZ553653A (enExample)
SG (1) SG163500A1 (enExample)
WO (1) WO2006026095A2 (enExample)
ZA (1) ZA201106419B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013177442A (ja) * 2004-08-10 2013-09-09 Taro Pharmaceutical Industries Ltd ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
JP2024505143A (ja) * 2021-01-12 2024-02-05 ベタゲノン アーベー 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CN100502871C (zh) 2002-12-11 2009-06-24 塔罗制药工业有限公司 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
KR102162003B1 (ko) 2014-04-14 2020-10-06 삼성전자주식회사 무선 네트워크 연결 제어 방법 및 장치
KR101822417B1 (ko) * 2017-06-14 2018-01-29 주식회사 청도제약 인간의 체액에서 산화 스트레스를 측정하기 위한 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08104629A (ja) * 1994-09-22 1996-04-23 Asta Medica Ag 経口適用のための服用形
JP2004517808A (ja) * 2000-07-26 2004-06-17 タロ ファーマシューティカル インダストリーズ リミテッド 神経保護剤としての非鎮静バルビツレート化合物
WO2004052350A2 (en) * 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119701A (en) * 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CN1896084A (zh) * 2002-01-30 2007-01-17 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08104629A (ja) * 1994-09-22 1996-04-23 Asta Medica Ag 経口適用のための服用形
JP2004517808A (ja) * 2000-07-26 2004-06-17 タロ ファーマシューティカル インダストリーズ リミテッド 神経保護剤としての非鎮静バルビツレート化合物
WO2004052350A2 (en) * 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012000737; Ｅｐｉｌｅｐｓｉａ ｖｏｌ．２０, 1979, ｐｐ．１０５-１１３ *
JPN6012000738; Ｅｐｉｌｅｐｓｉａ ２６（２）, 1985, ｐｐ．１５８-１６６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013177442A (ja) * 2004-08-10 2013-09-09 Taro Pharmaceutical Industries Ltd ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
JP2024505143A (ja) * 2021-01-12 2024-02-05 ベタゲノン アーベー 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド

Also Published As

Publication number Publication date
CA2576832A1 (en) 2006-03-09
WO2006026095A2 (en) 2006-03-09
EP1781294A4 (en) 2007-12-26
SG163500A1 (en) 2010-08-30
NZ553653A (en) 2010-06-25
ATE510541T1 (de) 2011-06-15
HK1108313A1 (en) 2008-05-02
CN102512422A (zh) 2012-06-27
BRPI0513337A (pt) 2008-05-06
AU2005280419B2 (en) 2010-09-23
EP1781294B1 (en) 2011-05-25
EP1625848A1 (en) 2006-02-15
JP2013177442A (ja) 2013-09-09
MX2007001655A (es) 2007-04-23
ZA201106419B (en) 2012-05-30
IL181247A0 (en) 2007-07-04
CA2576832C (en) 2013-06-11
KR20120130256A (ko) 2012-11-29
IL181247A (en) 2012-05-31
AU2005280419A1 (en) 2006-03-09
WO2006026095A3 (en) 2007-02-01
EP1781294A2 (en) 2007-05-09
KR20070074549A (ko) 2007-07-12
CN101052403A (zh) 2007-10-10

Similar Documents

Publication Publication Date Title
JP2013177442A (ja) ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
US11229652B2 (en) Treatments for autoimmune disease
US8076346B2 (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US20090124639A1 (en) valacyclovir formulations
JP5452843B2 (ja) 夜間の経口インスリン治療
EP1819323B2 (en) Pharmaceutical composition containing an anti-nucleating agent
TW202214555A (zh) 茚化合物、其醫藥組合物及其治療應用
ES2897475T3 (es) Composición y método para el tratamiento de trastornos metabólicos
US11236041B2 (en) Type-G crystal form of fenolamine, preparation method, composition and use thereof
JP2003507330A (ja) ベンズアミド誘導体を有効成分とする製剤
US6750249B1 (en) Controlled release oral preparations of esculetin and its derivatives
CN112457291B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
HK1108313B (en) Composition for improved bioavailability and enhanced brain delivery of 5, 5-diphenyl barbituric acid
HK1171958A (en) Composition and method for improved bioavailability and enhanced brain delivery of 5, 5-diphenyl barbituric acid
CN102126973A (zh) 一种二元酯酸的葡甲胺盐化合物,其制备方法和药物应用
WO2025045072A1 (zh) 一种酞嗪酮类化合物及其制备方法、药物组合物及用途
CN114533712A (zh) 减轻胃肠道副作用的药学组合物
HK1110515A (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130719

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130902

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20140106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140214